2025 Western Section of the American Urological Association (WSAUA)
WSAUA 2025 Prostate Cancer
- WSAUA 2025: Comparative Performance of UNFOLD AI, PSMA-PET, and mpMRI for Prostate Cancer Localization and Pathologic Staging
- WSAUA 2025: Head-to-Head Comparison of Multimodal Imaging in the Detection of Prostate Cancer Using Whole Mount Histopathology as a Reference
- WSAUA 2025: Impact of Bone Protecting Agents on Outcomes with Enzalutamide, with or without Radium-223, in Asymptomatic/mildly Symptomatic Patients with Bone mCRPC from PEACE-3
- WSAUA 2025: Genomic Classifier Scores and Risk of Histologic Upgrading on Confirmatory Biopsy During Active Surveillance
- WSAUA 2025: Efficacy and Safety of Darolutamide + ADT in Black Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase 3 ARANOTE Trial
WSAUA 2025 Bladder Cancer
- WSAUA 2025: CHAI Analysis of High-Grade Ta Non Muscle Invasive Bladder Cancer Risk Stratification for Progression and Recurrence Across Subgroups
- WSAUA 2025: Treatment of Low Grade Intermediate Risk Non Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study
- WSAUA 2025: Erdafitinib Use in Eligible Patients with Metastatic Urothelial Carcinoma: Results from the Veterans Health Administration
- WSAUA 2025: Nurse and Advanced Practice Provider Perspectives on TAR-200 Treatment of High Risk NMIBC in the Urology Clinic
- WSAUA 2025: Matching Adjusted Indirect Comparisons of TAR-200 versus FDA-Approved Novel Agents in BCG Unresponsive High-Risk NMIBC with CIS
WSAUA 2025 Kidney Cancer
WSAUA 2025 Upper Tract Urothelial Carcinoma
- WSAUA 2025: Long-Term Outcomes of Primary Chemoablation of New-Onset or Recurrent Low Grade Upper Tract Urothelial Carcinoma with UGN-101, a Mitomycin Reverse Thermal Gel
- WSAUA 2025: Baseline Characteristics From the uTRACT Registry Evaluating the Real-World use of UGN-101 in Participants with UTUC in the United States